Susana Garcia-Obregon1, Mikel Azkargorta2, Iratxe Seijas3, Javier Pilar-Orive4, Francisco Borrego5, Felix Elortza2, Maria Dolores Boyano6, Itziar Astigarraga7. 1. Pediatric Oncology Group, BioCruces Health Research Institute, 48903, Barakaldo, Spain. Electronic address: susana.garciaobregon@osakidetza.eus. 2. Proteomics Platform, CIC bioGUNE, CIBERehd, ProteoRed-ISCIII, Bizkaia Science and Technology Park, 48160, Derio, Spain. 3. Pediatric Oncology Group, BioCruces Health Research Institute, 48903, Barakaldo, Spain; Intensive Care Service, Hospital Universitario Cruces, 48903, Barakaldo, Spain. 4. Pediatric Critical Care Group, BioCruces Health Research Institute, 48903, Barakaldo, Spain; Pediatric Critical Care Service, Hospital Universitario Cruces, 48903, Barakaldo, Spain. 5. Immunopathology Group, BioCruces Health Research Institute, 48903, Barakaldo, Spain; Ikerbasque, Basque Foundation for Science, 48013, Bilbao, Spain. 6. Tumor Markers and Chemoresistance Group, BioCruces Health Research Institute, 48903, Barakaldo, Spain; Department of Cell Biology and Histology, Faculty of Medicine, University of the Basque Country, UPV/EHU, Leioa, 48940, Bizkaia, Spain. 7. Pediatric Oncology Group, BioCruces Health Research Institute, 48903, Barakaldo, Spain; Pediatric Service, Hospital Universitario Cruces, 48903, Barakaldo, Spain; Department of Pediatric, Faculty of Medicine, University of the Basque Country, UPV/EHU, Leioa, 48940, Bizkaia, Spain.
Abstract
BACKGROUND: Sepsis is a life-threatening illness with a challenging diagnosis. Current serum biomarkers are not sensitive enough for diagnosis. With the aim of finding proteins associated with sepsis, serum protein profile was compared between patients and healthy donors and serum classical inflammatory proteins were analyzed in both groups. METHODS: Serum protein profiles were characterized by two-dimensional electrophoresis (2DE). Identification of the proteins was carried out by mass spectrophotometry and their validation was performed by Enzyme-Linked-ImmunoSorbent Assay (ELISA) in a cohort of 85 patients and 67 healthy donors. Seven classical inflammatory proteins were analyzed in the same cohort by ELISA: interleukin-2 receptor α-chain (sCD25), scavenger receptor cysteine-rich-type-1 (sCD163), tumor-necrosis factor receptor superfamily-member-6 (sFas), hemeoxigenase-1 decycling (HO-1), interleukin-6 (IL-6), interleukin-18 (IL-18) and intercellular adhesion-molecule-1 (sICAM-1). RESULTS: After 2DE, 20 significantly differently expressed spots were identified by mass spectrometry analysis, revealing deregulation of six different proteins upon sepsis and 50% were validated by ELISA: Antithrombin-III (AT-III), Clusterin (CLUS) and Serum amyloid A-1 (SAA-1). Serum concentration of AT-III and CLUS was significantly lower in patients' serum, whereas SAA-1 showed higher values in septic patients. Serum concentration of the seven inflammatory proteins was significantly increased in septic patients. Functional analysis of the ten deregulated proteins revealed an enrichment of proteins related mainly to the activation of the immune response. CONCLUSION: We have identified a panel of ten potential sepsis marker proteins biologically connected and validated in a large number of patients, whose analysis could be considered as a complementary tool for the diagnosis of sepsis.
BACKGROUND:Sepsis is a life-threatening illness with a challenging diagnosis. Current serum biomarkers are not sensitive enough for diagnosis. With the aim of finding proteins associated with sepsis, serum protein profile was compared between patients and healthy donors and serum classical inflammatory proteins were analyzed in both groups. METHODS: Serum protein profiles were characterized by two-dimensional electrophoresis (2DE). Identification of the proteins was carried out by mass spectrophotometry and their validation was performed by Enzyme-Linked-ImmunoSorbent Assay (ELISA) in a cohort of 85 patients and 67 healthy donors. Seven classical inflammatory proteins were analyzed in the same cohort by ELISA: interleukin-2 receptor α-chain (sCD25), scavenger receptor cysteine-rich-type-1 (sCD163), tumor-necrosis factor receptor superfamily-member-6 (sFas), hemeoxigenase-1 decycling (HO-1), interleukin-6 (IL-6), interleukin-18 (IL-18) and intercellular adhesion-molecule-1 (sICAM-1). RESULTS: After 2DE, 20 significantly differently expressed spots were identified by mass spectrometry analysis, revealing deregulation of six different proteins upon sepsis and 50% were validated by ELISA: Antithrombin-III (AT-III), Clusterin (CLUS) and Serum amyloid A-1 (SAA-1). Serum concentration of AT-III and CLUS was significantly lower in patients' serum, whereas SAA-1 showed higher values in septicpatients. Serum concentration of the seven inflammatory proteins was significantly increased in septicpatients. Functional analysis of the ten deregulated proteins revealed an enrichment of proteins related mainly to the activation of the immune response. CONCLUSION: We have identified a panel of ten potential sepsis marker proteins biologically connected and validated in a large number of patients, whose analysis could be considered as a complementary tool for the diagnosis of sepsis.
Authors: Erin Harberts; Tao Liang; Sung Hwan Yoon; Belita N Opene; Melinda A McFarland; David R Goodlett; Robert K Ernst Journal: J Proteome Res Date: 2020-02-24 Impact factor: 4.466
Authors: Thanusi Thavarajah; Claudia C Dos Santos; Arthur S Slutsky; John C Marshall; Pete Bowden; Alexander Romaschin; John G Marshall Journal: Clin Proteomics Date: 2020-07-02 Impact factor: 3.988
Authors: Alexander Hahn; Melanie Kny; Cristina Pablo-Tortola; Mihail Todiras; Michael Willenbrock; Sibylle Schmidt; Katrin Schmoeckel; Ilka Jorde; Marcel Nowak; Ernst Jarosch; Thomas Sommer; Barbara M Bröker; Stephan B Felix; Claus Scheidereit; Steffen Weber-Carstens; Christian Butter; Friedrich C Luft; Jens Fielitz Journal: J Cachexia Sarcopenia Muscle Date: 2019-08-23 Impact factor: 12.910
Authors: Tomislav Čaval; Yu-Hsien Lin; Meri Varkila; Karli R Reiding; Marc J M Bonten; Olaf L Cremer; Vojtech Franc; Albert J R Heck Journal: Front Immunol Date: 2021-01-14 Impact factor: 7.561